A Thermostable Oral SARS-CoV-2 Vaccine Induces Mucosal and Protective Immunity - Immunologie-Immunopathologie-Immunothérapie Accéder directement au contenu
Article Dans Une Revue Frontiers in Immunology Année : 2022

A Thermostable Oral SARS-CoV-2 Vaccine Induces Mucosal and Protective Immunity

Résumé

An ideal protective vaccine against SARS-CoV-2 should not only be effective in preventing disease, but also in preventing virus transmission. It should also be well accepted by the population and have a simple logistic chain. To fulfill these criteria, we developed a thermostable, orally administered vaccine that can induce a robust mucosal neutralizing immune response. We used our platform based on retrovirus-derived enveloped virus-like particles (eVLPs) harnessed with variable surface proteins (VSPs) from the intestinal parasite Giardia lamblia , affording them resistance to degradation and the triggering of robust mucosal cellular and antibody immune responses after oral administration. We made eVLPs expressing various forms of the SARS-CoV-2 Spike protein (S), with or without membrane protein (M) expression. We found that prime-boost administration of VSP-decorated eVLPs expressing a pre-fusion stabilized form of S and M triggers robust mucosal responses against SARS-CoV-2 in mice and hamsters, which translate into complete protection from a viral challenge. Moreover, they dramatically boosted the IgA mucosal response of intramuscularly injected vaccines. We conclude that our thermostable orally administered eVLP vaccine could be a valuable addition to the current arsenal against SARS-CoV-2, in a stand-alone prime-boost vaccination strategy or as a boost for existing vaccines.
Fichier principal
Vignette du fichier
bellier.pdf (4.75 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03868328 , version 1 (23-11-2022)

Identifiants

Citer

Bertrand Bellier, Alicia Saura, Lucas A Luján, Cecilia R Molina, Hugo D Luján, et al.. A Thermostable Oral SARS-CoV-2 Vaccine Induces Mucosal and Protective Immunity. Frontiers in Immunology, 2022, 13, pp.837443. ⟨10.3389/fimmu.2022.837443⟩. ⟨hal-03868328⟩
54 Consultations
19 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More